Skip to main content
TipRanks
Go Ultimate75% OFF

Integer Holdings (ITGR) AI Stock Analysis

160 Followers
ITGR

Integer Holdings

(NYSE:ITGR)

Select Model
Rating:63Neutral
Price Target:$135.00â–²(6.55% Upside)
Action:reiterated
Date:10/29/26

The score is driven primarily by mid-tier financial performance: decent margins and manageable leverage, but a sharp TTM revenue decline and operating margin compression are meaningful near-term risks. Technicals are moderately supportive with price above longer-term averages and positive MACD. Valuation is a headwind due to a high P/E and no dividend yield provided. Corporate events are a positive offset given the advanced, shareholder-approved take-private transaction.

Positive Factors
Specialized medical-device CDMO platformInteger’s integrated CDMO capabilities span development through production for complex, regulated medical devices. This breadth can deepen OEM relationships, support repeat manufacturing programs, and create switching friction as customers rely on validated processes and specialized technical expertise.
Negative Factors
Sharp TTM revenue declineThe sharp TTM revenue decline interrupts Integer’s previously steady multi-year expansion and weakens the near-term growth profile. Sustained lower revenue could reduce manufacturing utilization, constrain operating leverage, and make it harder for the company to fund capacity or innovation at prior levels.

Integer Holdings Key Performance Indicators (KPIs)

Revenue by SegmentBreaks down sales across the company’s business units or product lines to show which areas drive growth and profits. Highlights dependence on any single segment or customer, differences in margins across lines, and where future expansion or downside risk is likely to come from — essential for judging Integer’s diversification, stability of cash flow, and how acquisitions or shifts in end markets will affect results.

$0.00$100.00M$200.00M$300.00M$400.00M$500.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Cardio & Vascular has been the primary growth engine and remains central to Integer’s trajectory, but management warns of temporary EP normalization that could pause that momentum; CRM&N looks steady but is flattening, while Other Markets and the non‑medical electrochem line have been effectively removed from the growth mix (portfolio exits/reclassifications), increasing reliance on core med‑tech sales. That concentration helps explain rising top‑line resilience alongside the company’s margin and cash‑flow pressures, motivating cost actions, buybacks and a board‑led strategic review.

Data provided by:The Fly

Integer Holdings (ITGR) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%100%ITGR+87.01%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$4.31B
Dividend Yield
―
Average Volume (3M)
790.83K
Price to Earnings (P/E)
42.2
Beta (1Y)
0.42
Revenue Growth
-0.33%
EPS Growth
20.67%
Country
US
Employees
11,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Integer Holdings Business Overview & Revenue Model

Company Description

Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into t...

How the Company Makes Money

Integer primarily makes money by providing contract development and manufacturing services to medical device OEMs, earning revenue from producing and supplying components, subassemblies, and finished/finished-ready medical devices under customer cont...

Integer Holdings Earnings Call Summary

Earnings Call Date:Apr 30, 2026(Q1-2026)|% Change Since:51.43%|Next Earnings Date:Feb 18, 2027
Earnings Call SentimentNeutral

The call conveyed a mixed picture: a modest top-line improvement in Q1 (reported +0.5%, organic +1.3%) and several strategic positives (share buybacks, lower interest expense, targeted cost actions, pipeline strength and a Board-initiated strategic review) were offset by meaningful near-term profitability pressures (adjusted operating income down 14%, margin contraction of 230 bps), weaker cash flow in Q1, and a downward revision to full-year 2026 revenue and profit guidance. Management characterizes the demand softness—primarily in electrophysiology—as temporary normalization and emphasized actions to protect long-term growth, but the guidance cuts and margin contraction represent notable near-term headwinds.

Positive Updates

Quarterly Revenue Growth
Q1 2026 sales of $440 million, up 0.5% on a reported basis and up 1.3% on an organic basis versus the prior year.

Negative Updates

Operating Profitability Decline
Adjusted operating income declined 14% year-over-year in Q1 and adjusted operating margin contracted by 230 basis points to 13.9%, driven primarily by lower fixed cost absorption.

Company Guidance

Integer updated its 2026 guidance with full‑year reported sales now expected at $1.805–$1.835 billion (down 1%–3% YoY) and organic sales flat to down 1% (including a ~3%–4% headwind from three new products; organic growth excluding those products ~3%–4%); inorganic decline ~1% (Portable Medical exit); C&V expected flat to down low‑single digits, CRM&N flat to up low‑single digits, and other markets down ~$34M–$36M. Profitability outlook: adjusted EBITDA $375M–$399M (down 1%–7%), adjusted operating income $285M–$305M (down 5%–11%) with sequential margin improvement expected (Q2 operating margin +80–140 bps and continuing improvement through 2026), adjusted net income $200M–$220M (down 3%–11%) and adjusted EPS $5.83–$6.40 (flat to down 9%). Cash/debt targets: cash flow from operations $185M–$205M (≈$15M lower at midpoint), CapEx $95M–$105M (~5%–6% of sales), free cash flow $85M–$105M, year‑end net total debt $1.185B–$1.205B and leverage expected in the 2.5x–3.5x trailing‑4Q adjusted EBITDA target range (Q1 net total debt $1.264B, leverage 3.2x). Q1 actuals and drivers: sales $440M (+0.5% reported, +1.3% organic), adjusted EBITDA $85M (‑7%), adjusted operating margin 13.9% (‑230 bps), adjusted net income $41M (‑10%), adjusted EPS $1.20 (‑8%), cash from ops $25M, CapEx $24M, free cash flow $1M; interest expense was $4M lower (helping EPS by ~$0.10), and share repurchases of $50M in Q4 ’25 (~700k shares) and $50M in Q1 ’26 (~600k shares) reduced weighted shares ~2% (adding ~$0.02 to EPS).

Integer Holdings Financial Statement Overview

Summary

Financials are solid but uneven. Revenue grew over 2021–2025, yet the TTM shows a sharp reported revenue decline and operating margin compression versus the 2024 peak (EBIT margin ~13.0% in 2024 vs ~9.5% TTM). Profitability is still decent (TTM net margin ~7.0%, EBITDA margin ~17.0%) and the balance sheet is reasonably leveraged (debt ~0.79x equity) with acceptable ROE (~7.4%). Free cash flow is positive (~$149M TTM) but conversion is mixed (OCF ~0.95x net income; FCF ~55% of net income). Segment KPIs indicate growing reliance on Cardio & Vascular while Other Markets deteriorated, which adds concentration risk.

Income Statement

62Positive

Balance Sheet

66Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.82B1.85B1.72B1.56B1.33B1.22B
Gross Profit430.19M425.81M461.18M411.52M346.65M336.97M
EBITDA286.19M298.38M334.26M277.56M222.84M224.43M
Net Income103.70M102.76M119.90M90.65M66.38M96.81M
Balance Sheet
Total Assets3.39B3.41B3.08B2.94B2.79B2.58B
Cash, Cash Equivalents and Short-Term Investments14.13M17.16M46.54M23.67M24.27M17.89M
Total Debt1.34B1.40B1.10B1.05B1.01B905.81M
Total Liabilities1.67B1.66B1.46B1.42B1.38B1.23B
Stockholders Equity1.73B1.75B1.62B1.52B1.42B1.35B
Cash Flow
Free Cash Flow81.82M105.12M99.85M60.27M41.65M103.20M
Operating Cash Flow176.48M196.15M205.21M180.21M116.38M156.67M
Investing Cash Flow-116.57M-270.73M-195.41M-163.37M-200.42M-271.00M
Financing Cash Flow-103.90M43.56M13.32M-18.01M92.48M81.99M

Integer Holdings Technical Analysis

Technical Analysis SentimentPositive
Last Price126.70

Price Trends

50DMA126.47Positive
100DMA118.39Positive
200DMA102.84Positive

Market Momentum

MACD0.14Positive
RSI58.88Neutral
STOCH47.03Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITGR, the sentiment is Positive. The current price of 126.70 is above the 20-day moving average (MA) of 126.61, above the 50-day MA of 126.47, and above the 200-day MA of 102.84, indicating a bullish trend. The MACD of 0.14 indicates Positive momentum. The RSI at 58.88 is Neutral, neither overbought nor oversold. The STOCH value of 47.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ITGR.

Integer Holdings Risk Analysis

Integer Holdings disclosed 43 risk factors in its most recent earnings report. Integer Holdings reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.The pending Merger may be delayed or not occur at all for a variety of reasons, including that the Merger is terminated, and the failure to complete the Transaction could adversely affect our business, results of operations, financial condition, and the market price of our common stock.Q2, 2026
2.Efforts to complete the Merger could disrupt our relationships with third parties and employees, divert management's attention, or result in negative publicity or legal proceedings, any of which could negatively impact our operating results and ongoing business.Q2, 2026
3.While the Merger Agreement is in effect, we are subject to restrictions on our business activities.Q2, 2026

Integer Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ITGR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
UFPTUFPT81Outperform$2.36B30.8116.90%―8.62%13.50%
LIVNLIVN77Outperform$5.03B25.5115.35%―11.71%―
HAEHAE71Outperform$5.60B54.1612.07%―4.11%-34.22%
ITGRITGR63Neutral$4.31B42.236.02%―-0.33%20.67%
NSYSNSYS62Neutral$30.89M16.645.14%―9.04%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IARTIART44Neutral$1.12B85.821.24%―0.84%―

* Healthcare Sector Average

Performance Comparison

0%50%100%150%ITGRHAEIARTNSYSUFPTLIVNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ITGR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ITGRInteger Holdings126.7059.6088.82%
HAEHaemonetics122.9448.6265.42%
IARTIntegra Lifesciences14.402.6722.76%
NSYSNortech10.783.7453.12%
UFPTUfp Technologies305.0682.2436.91%
LIVNLivaNova PLC91.3237.6870.25%

Integer Holdings Corporate Events

M&A TransactionsShareholder Meetings

Integer Holdings shareholders overwhelmingly approve KKR acquisition

Positive
Oct 21, 2026

On October 21, 2026, Integer Holdings Corporation stockholders met at a special meeting to vote on proposals tied to a planned merger with Armstrong Parent, Inc., an affiliate of investment funds managed by Kohlberg Kravis Roberts & Co. L.P. Sharehol...

Business Operations and StrategyRegulatory Filings and Compliance

Integer Holdings Issues Forward-Looking Strategic Disclosure Statement

Neutral
Oct 14, 2026

Integer Holdings issued a brief communication referencing conditions or developments that may occur in the future and the timing of such matters, without providing specific operational or financial details. The statement suggests the company is addre...

Business Operations and StrategyPrivate Placements and Financing

Integer Holdings Opens Convertible Notes Conversion Window

Neutral
Oct 2, 2026

On October 2, 2026, Integer Holdings Corporation announced that its 2.125% Convertible Senior Notes due 2028 became convertible at the option of holders for the calendar quarter beginning October 1 and ending December 31, 2026. The Notes can be conve...

M&A TransactionsRegulatory Filings and ComplianceShareholder Meetings

Integer Holdings Advances Toward KKR Acquisition Completion

Positive
Sep 30, 2026

Integer Holdings Corporation, a major medical device contract developer and manufacturer serving cardio and vascular, neuromodulation and cardiac rhythm management markets, operates globally under brands such as Greatbatch Medical and Lake Region Med...

Delistings and Listing ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings

KKR to Take Integer Holdings Private in Buyout

Positive
Aug 4, 2026

On August 2, 2026, Integer Holdings Corporation agreed to be acquired by Armstrong Parent, Inc., an affiliate of funds managed by Kohlberg Kravis Roberts & Co. L.P., in a cash merger that will take the company private at $127 per share. The transacti...

Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresM&A Transactions

KKR to Take Integer Holdings Private in Merger

Positive
Aug 3, 2026

On August 3, 2026, Integer Holdings agreed to be acquired by an affiliate of KKR in an all-cash merger valuing the company at about $5.7 billion, with shareholders set to receive $127 per share, a significant premium to pre-review trading levels. The...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 29, 2026